PRACTICE AREAS« View All Practice Areas
Hausfeld LLP attorneys have achieved notable success in representing clients injured by unsafe drugs, faulty medical devices, and other defective products. These cases are often called "mass torts" due to the large numbers of people injured by similar products.
Attorneys from Hausfeld LLP have litigated many of the most important pharmaceutical cases in the last decade. Richard Lewis of Hausfeld LLP was one of the lead lawyers in the $3.75 billion settlement of the case against the manufacturer of the diet drugs Redux (dexfenfluramine) and Pondimin (fenfluramine). The settlement involves millions of U.S. consumers who used the diet drugs, often with another drug called phentermine, in what was commonly referred to as "fen-phen." Patients taking Redux and Pondimin were found to be at greater risk for heart valve damage and an often fatal lung disease, primary pulmonary hypertension. The settlement provided compensation for those injured, and medical monitoring for millions of U.S. consumers who took the drugs but did not yet show symptoms of an injury.
Hausfeld LLP is actively involved litigating pharmaceutical cases against the makers of hormone replacement therapy ("HRT") which is known to cause breast cancer. Hausfeld attorneys also represent injured consumers who were prescribed the prescription drugs: Vioxx, Bextra and Celebrex, which have been associated with heart attacks and strokes. The Firm’s lawyers also filed one of the first cases against the makers of the addictive drug, OxyContin. Working with the State of West Virginia, Hausfeld LLP attorneys helped secure a $10 million settlement from Purdue Pharma, LLP, the manufacturer and marketer of OxyContin.
Cases and Current Investigations
- Fen-Phen: In re Diet Drug Litigation, MDL No. 1203 (E.D.Pa.)
As a member of the Plaintiffs' Management Committee and Sub-Class Counsel, Richard S. Lewis played a significant part in the success of the Fen-Phen diet drug litigation and settlement. Plaintiffs' counsel achieved one of the largest settlements ever obtained in a mass tort case - $3.75 billion - on behalf of millions of U.S. consumers who used Pondimin (fenfluramine) or Redux (dexfenfluramine) either alone or in combination with phentermine, diet drugs that are associated with heart valve damage.
- PPA: In re Phenulpropanolamine (PPA) Products Liability Litigation, MDL No. 1407 (W.D.Wa.)
Hausfeld LLP lawyer Richard S. Lewis served as co-lead counsel in the mass tort litigation involving OTC medication that led to strokes and numerous product recalls, which resulted in the nationwide settlement in 2004 of all PPA-related injury claims resulting from the ingestion of Dexatrim.
- OxyContin: West Virginia v. Purdue Pharma Co,, (Cir. Ct. WV.)
Hausfeld LLP lawyers represented West Virginia Attorney General Darrell V. McGraw, Jr. in a suit against Purdue Pharma and Abbott Laboratories, the manufacturers and promoters of the painkiller OxyContin. The complaint alleged that Pharma and Abbott engaged in negligent aggressive marketing practices which encouraged over-prescription of this powerful narcotic resulting in addiction and overdoses. The lawsuit sought to stop the aggressive and deceptive marketing techniques used in West Virginia, as well as monies to help record, prevent and halt OxyContin abuse. After two years of litigation, and just before a jury was selected to try the case, Purdue Pharma settled the case with the State of West Virginia for $10 million.
- HRT: In re Prempro Products Litigation MDL No. 1508 (E.D. Ark.)
Hausfeld LLP lawyer Richard S. Lewis served as a member of the Plaintiffs Steering Committee in this litigation which resulted in the successful resolution of thousands of claims filed by women who took HRT and suffered breast cancer.
- Stents: Bowman v. Midei (Cir. Ct. Md.)
Hausfeld LLP lawyer Richard S. Lewis served as trial counsel with Gerry Mitchell and Jay Miller in the trial of 21 test plaintiffs seeking damages for the unnecessary placement of cardiac stents. After three weeks of trial, the Plaintiffs obtained a successful settlement for the 21 test plaintiffs in trial and approximately 230 other plaintiffs with similar claims against defendants St. Joseph Medical Center, Catholic Health Initiatives, and Dr. Mark Midei.